Publication Date
2024
Document Type
Article
Abstract
treatment in many clinical scenarios. Trauma centers are noting an increase in patients presenting on these medications. The 2018 Food and Drug Administration approval of andexanet alfa provides an alternative anticoagulation reversal. Barriers may limit utilization of new medications including a lack of grade 1A evidence supporting the use of prothrombin complex concentrate (PCC) versus andexanet alfa and cost. To evaluate barriers of andexanet alfa utilization by trauma surgeons, a 15-question survey was conducted. There was a 9% completion rate (n = 89). The results revealed 23.5% would choose andexanet alfa as first-line treatment in children, and 25.8% as first-line treatment in adults. The majority of respondents, 64.7% and 67.4%, would use PCC preferentially in children and adults, respectively. Respondents indicated that cost burden was an overriding factor (76.3%); 42.4% cited lack of high-level efficacy data of andexanet alfa for reversal of factor Xa inhibitors. Additional double-blinded multi-institutional randomized controlled trials comparing 4F-PCC and andexanet alfa for factor Xa inhibitor reversal are needed to support efficacy especially with the increased cost associated.
DOI
10.1177/10760296241238013
Journal Title
Clinical and Applied Thrombosis/Hemostasis
Volume (Issue)
30 (2024)
Journal ISSN
1076-0296
Recommended Citation
Fasanya, Charles MD, FRCS, FACS; Arrillaga, Abenamar MD, FACS, FCCP; Caronia, Catherine MC, MBA; Rothburd, Lauren BS; Japhe, Tenzing BA; Hahn, Younghee BS; Joseph, Paul BS; Reci, Dajana BA; and Eckardt, Patricia A. PhD, RN, FAAN, "Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey" (2024). Faculty Publications: Nursing. 2.
https://digitalcommons.molloy.edu/nur_facpub/2
Document Version
Publisher's PDF
Publisher's Statement
© The Author(s) 2024
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
